Tableaux LLC Takes $67.73 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Tableaux LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, HoldingsChannel.com reports. The fund acquired 129,000 shares of the biopharmaceutical company’s stock, valued at approximately $67,725,000. Regeneron Pharmaceuticals makes up about 4.8% of Tableaux LLC’s holdings, making the stock its 5th biggest holding.

A number of other large investors have also modified their holdings of REGN. PGGM Investments lifted its position in shares of Regeneron Pharmaceuticals by 159.7% during the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock valued at $44,308,000 after buying an additional 51,900 shares in the last quarter. Founders Capital Management LLC raised its position in Regeneron Pharmaceuticals by 7.0% during the second quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock worth $4,344,000 after acquiring an additional 538 shares during the period. Sepio Capital LP lifted its holdings in Regeneron Pharmaceuticals by 33.1% during the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock valued at $2,150,000 after purchasing an additional 842 shares in the last quarter. Generate Investment Management Ltd purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $6,300,000. Finally, Bellecapital International Ltd. lifted its position in shares of Regeneron Pharmaceuticals by 32.7% in the second quarter. Bellecapital International Ltd. now owns 25,503 shares of the biopharmaceutical company’s stock valued at $13,389,000 after acquiring an additional 6,283 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In related news, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the transaction, the director owned 2,352 shares in the company, valued at $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $755.90 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $800.99. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06. The firm’s 50 day moving average price is $615.29 and its 200-day moving average price is $575.60. The firm has a market cap of $79.44 billion, a P/E ratio of 18.10, a P/E/G ratio of 2.03 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.73 by $2.10. The firm had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.Regeneron Pharmaceuticals’s revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the company earned $12.46 EPS. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is presently 8.43%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on REGN shares. Raymond James Financial raised Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. BMO Capital Markets increased their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a research report on Monday, August 4th. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 14th. Sanford C. Bernstein increased their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a report on Wednesday, August 27th. Finally, Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, November 17th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $776.81.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.